Bank of America (NYSE: BAC) is slated to report second-quarter financial results before the opening bell on Wednesday, July 17. The market remains quite muted ahead of the results, reflecting yet another quarter of weak equity trading.
Earlier this week, when rival Citigroup (NYSE: C) posted better-than-expected Q2 results, it was primarily due to one-off costs associated with an IPO and not market tailwinds at play.
For Bank of America, the street consensus for revenue is $23.25 billion, a modest 2% growth from the same period a year ago.
Performance at its Global Wealth and Investment Management division, which accounted for over 14% of its overall revenue, was likely hurt by a slowing economy and trade tensions. Though some major deals were sealed during the quarter, a spike in borrowing costs weighed on deal value.
Investment banking revenues primarily comprise underwriting and advisory fees associated with acquisitions and public offerings. Equity issuance was quite strong in the second quarter, helped by a dovish stance by the Federal Reserve, but most of this could be offset by weak debt issuance, which was hurt by higher interest rates.
Trading revenues are likely to decline year-over-year on dismal client activity and low volatility. Net interest income also may not please investors due to unenthusiastic industrial and commercial lending during this period.
Meanwhile, the bottom-line is expected to grow to 71 cents per share from 63 cents per share a year ago, helped by the company’s cost-cutting initiatives. Keep your ears open for any management comments relating to its cost optimization initiatives as well as its contingency plan in the event of continued decline in trading volatility.
READ: Bank of America Q1 2019 earnings conference call transcript
It may be noted that Bank of America has a remarkable history of beating earnings consensus.
BAC stock is currently 28% above its 52-week low to which, it had plunged last December. The stock has an average 12-month average price target of $32.83, suggesting a 13% upside from the last close.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on